TD Cowen analyst Marc Frahm has maintained their bullish stance on NUVL stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Marc Frahm has given his Buy rating due to a combination of factors, chiefly the strength and de‑risked profile of Nuvalent’s late‑stage pipeline. He highlights neladalkib as a potentially category‑leading ALK inhibitor with pivotal 2L+ data that support both regulatory approval and rapid uptake in a sizable existing market, with room to expand that opportunity meaningfully.
He also points to zidesamtinib’s compelling efficacy and clean safety across ROS1‑positive settings, with an FDA decision in 2L+ expected in 2026 and a first‑line filing targeted for the same year, positioning Nuvalent for multiple launches. Combined with robust cash reserves that extend into 2029 and strong trial enrollment trends, he views the company as well funded and on track to convert its clinical assets into commercial revenue, supporting a positive risk‑reward profile for the stock.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $142.00 price target.